LeafNLP Demos
Back to explore

Report #2887126

Received Feb 27, 2026

Reports are unverified and do not show that a vaccine caused an event. Full disclaimer

Overview

Sex
Female
Age
Age unknown
State
LA
Recovered
Unknown
Vaccinated
Sep 1, 2025
Onset
Sep 1, 2025
Days to onset
0
Hospital days
—

Vaccines (1)

TypeNameManufacturerDoseLotRoute / Site
VARZOSZOSTER (SHINGRIX)GLAXOSMITHKLINE BIOLOGICALS2UNK—

Symptoms (1)

Inappropriate schedule of product administration

Symptom narrative

did not receive a 2nd dose until September of 2025; This non-serious case was reported by a consumer via call center representative and described the occurrence of drug dose administration interval too long in a 76-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis. Previously administered products included Shingrix (1st dose was taken in 2023). Concurrent medical conditions included hypothyroidism, pulse rate, blood pressure and migraine (migraine breakthrough). Concomitant products included rivaroxaban (Xarelto), thyroid (Armour Thyroid), metoprolol, acetylsalicylic acid (Asprin), erenumab aooe (Aimovig) and rimegepant sulfate (Nurtec Odt). In SEP-2025, the patient received the 2nd dose of Shingrix (unknown arm). In SEP-2025, an unknown time after receiving Shingrix, the patient experienced drug dose administration interval too long (Verbatim: did not receive a 2nd dose until September of 2025). The outcome of the drug dose administration interval too long was not applicable. Additional Information: GSK receipt date 20-FEB-2026 The batch number was not provided and a request for this information has been made.

Current illness

Blood pressure; Hypothyroidism; Migraine (migraine breakthrough); Pulse rate

Other medications

XARELTO; ARMOUR THYROID; METOPROLOL; ASPRIN; Aimovig; NURTEC ODT